The ongoing INNOVATION trial, which is testing trastuzumab or trastuzumab and pertuzumab as a perioperative treatment in patients with HER2-positive resectable G/GEJ adenocarcinoma, indicates that this therapy may be the standard of care in the perioperative period [48]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.